News brief­ing: Al­ny­lam wins EC OK for its third drug, putting them out front on PH1; Big biotech VC Qim­ing clos­es out Fund VII with $1.2B

Al­ny­lam $AL­NY put out word to­day that the Eu­ro­pean Com­mis­sion has ap­proved its third drug, lumasir­an, for pri­ma­ry hy­per­ox­aluria type 1, bet­ter known as PH1. It will be mar­ket­ed as Oxlu­mo.

An ul­tra rare ge­net­ic con­di­tion, Al­ny­lam CEO John Maraganore says there are on­ly some 1,000 to 1,700 pa­tients in the US and Eu­rope at any par­tic­u­lar point. The pa­tients, most­ly kids, suf­fer from an over­pro­duc­tion of ox­alate in the liv­er that spurs the de­vel­op­ment of kid­ney stones, right through to end stage kid­ney dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER